摘要
睑板腺功能障碍(MGD)是一种慢性、弥漫性睑板腺异常,其病因众多,发病机制复杂且患病率高,已经成为临床上常见的眼表疾病之一。MGD的治疗是近年来临床研究的热点和难点,主要包括改善生活方式、物理治疗、药物治疗、手术治疗,其中药物治疗占重要地位。按照作用机制可将治疗MGD的药物大致分为3大类:第1类是改善泪液质量和泪膜稳定性的药物,包括人工泪液和眼表润滑剂、促泌剂(促进脂质、水液以及黏蛋白分泌)和雄激素等;第2类是改善眼表微环境的药物,包括局部及全身应用抗生素、糖皮质激素类滴眼液、非甾体类抗炎药、免疫抑制剂、除螨药物等;第3类是营养补充剂和神经保护剂,包括维生素D3、ω-3脂肪酸、自体血清等。本文就目前临床常用及研究较多的MGD治疗药物进行综述,为MGD临床治疗和研究提供参考。
Meibomian gland dysfunction(MGD)is a chronic,diffuse meibomian gland disorder,which has complex pathogenesis and high prevalence.It has become one of the common ocular surface diseases in clinics,and its treatment has been the clinical research focus and a challenge over the years.The traditional treatments consist of lifestyle improvement,physical therapy,medical treatments and surgery,in which drug plays an important role.According to the etiology and pathogenesis of MGD,the applied drugs can be classified into three categories.The first category is to improve the quality of tears and the stability of tear film,including artificial tear and ocular surface lubricants,secretagogues(promoting the secretion of lipids,aqueous solution and mucin),androgens,etc.The second category is to improve the ocular surface microenvironment,including local and systemic antibiotics,glucocorticoid eyedrops,non-steroidal anti-inflammatory drugs,immunosuppressants,anti-mites drugs,etc.The third category is nutritional supplements and neuroprotectants,including vitamin D3,omega-3 fatty acids,autologous serum and so on.This review focused on widely-used and current emerging treatment options,aiming to provide references for clinical treatments and further study on MGD.
作者
黎颖莉(综述)
刘祖国(审校)
Li Yingli;Liu Zuguo(Department of Ophthalmology,Zhujiang Hospital,Southern Medical University/The Second School of Clinical Medicine,Southern Medical University,Guangzhou 510280,China;Affiliated Xiamen Eye Center of Xiamen University,Xiang'an Affiliated Hospital of Xiamen University,Eye Institute of Xiamen University,Xiamen 361102,China)
出处
《中华实验眼科杂志》
CAS
CSCD
北大核心
2023年第5期493-498,共6页
Chinese Journal Of Experimental Ophthalmology
基金
国家自然科学基金项目(81800804)
广东省教育厅高水平大学建设经费南方医科大学临床研究启动项目(LC2016YM017)。
关键词
睑板腺功能障碍
干眼
药物治疗
Meibomian gland dysfunction
Dry eye
Drug therapy
